IP Library Patent Application 13006822
Patent Application
App. No. 13/006,822

MULTIPOTENT STEM CELLS AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/006,822
Abstract

The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided.

Claims (11)

1 - 58 . (canceled)

59 . An isolated adult stem cell which is capable of proliferating and differentiating into ectoderm, mesoderm, and endoderm, expresses at least one of Oct-4, Nanog, and Sox-2, and does not detectibly express CD13, CD45, CD90, and CD34.

60 . An isolated adult quiescent stem cell which is capable of proliferating and differentiating into ectoderm, mesoderm, and endoderm and does not detectibly express Oct-4, CD13, CD45, CD90, and further does not detectibly express at least one of MHC class I, MHC class II, CD44, CD105, CD49c, and CD73.

61 . An isolated adult stem cell which is capable of proliferating and differentiating into ectoderm, mesoderm, and endoderm, expresses at least one of Oct-4, Nanog, and Sox-2, and does not detectibly express CD13, CD45, CD90, CD34 and further does not detectibly express at least one of MHC class I, MHC class II, CD44, CD105, CD49c, and CD73.

62 . The cell of claim 59 , wherein said cell is synovial fluid derived, blood derived or tissue derived.

63 . The cell of claim 59 , wherein said cell is substantially purified.

64 . The cell of claim 59 , wherein said cell is isolated from a mammal.

65 . The cell of claim 04 , wherein said cell is isolated from a human.

66 . The cell of claim 59 , wherein said cell is isolated from an adult mammal.

67 . The cell of claim 59 , comprising a heterologous nucleic acid sequence.

68 . A population of cells wherein at least 10% of the cells are the stem cells of claim 59 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2015
From: CRAWFORD, KEITH D.; SOUTHGATE, CHRISTOPHER
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 036218/0156 →
SECURITY INTEREST Recorded May 6, 2014
From: PARCELL LABORATORIES, INC.
To: JED FAMILY TRUST; WARSON FUND III, LLC; RUBIN, MARK H.; JOHNSTONE, BRUCE; JOHNSTONE ISSUE TRUST
Reel/Frame 032831/0625 →